Abstract
8155 AIM: This Prospective Phase II study was undertaken to determine whether a dose-modified gemcitabine-cisplatin regimen improved QOL, reduced toxicity, increased compliance and improved deliver...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
